BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

202 related articles for article (PubMed ID: 30061244)

  • 1. The Impact of EndoPredict Clinical Score on Chemotherapy Recommendations in Women with Invasive ER
    Mokbel K; Wazir U; Wazir A; Kasem A; Mokbel K
    Anticancer Res; 2018 Aug; 38(8):4747-4752. PubMed ID: 30061244
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A Comparison of the Performance of EndoPredict Clinical and NHS PREDICT in 120 Patients Treated for ER-positive Breast Cancer.
    Mokbel K; Wazir U; El Hage Chehade H; Manson A; Choy C; Moye V; Mokbel K
    Anticancer Res; 2017 Dec; 37(12):6863-6869. PubMed ID: 29187466
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prediction of chemotherapy benefit by EndoPredict in patients with breast cancer who received adjuvant endocrine therapy plus chemotherapy or endocrine therapy alone.
    Sestak I; Martín M; Dubsky P; Kronenwett R; Rojo F; Cuzick J; Filipits M; Ruiz A; Gradishar W; Soliman H; Schwartzberg L; Buus R; Hlauschek D; Rodríguez-Lescure A; Gnant M
    Breast Cancer Res Treat; 2019 Jul; 176(2):377-386. PubMed ID: 31041683
    [TBL] [Abstract][Full Text] [Related]  

  • 4. First prospective outcome data for the second-generation multigene test Endopredict in ER-positive/HER2-negative breast cancer.
    Ettl J; Anders SI; Hapfelmeier A; Paepke S; Noske A; Weichert W; Klein E; Kiechle M
    Arch Gynecol Obstet; 2020 Dec; 302(6):1461-1467. PubMed ID: 32902674
    [TBL] [Abstract][Full Text] [Related]  

  • 5. EndoPredict improves the prognostic classification derived from common clinical guidelines in ER-positive, HER2-negative early breast cancer.
    Dubsky P; Filipits M; Jakesz R; Rudas M; Singer CF; Greil R; Dietze O; Luisser I; Klug E; Sedivy R; Bachner M; Mayr D; Schmidt M; Gehrmann MC; Petry C; Weber KE; Kronenwett R; Brase JC; Gnant M;
    Ann Oncol; 2013 Mar; 24(3):640-7. PubMed ID: 23035151
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prognostic ability of EndoPredict compared to research-based versions of the PAM50 risk of recurrence (ROR) scores in node-positive, estrogen receptor-positive, and HER2-negative breast cancer. A GEICAM/9906 sub-study.
    Martin M; Brase JC; Ruiz A; Prat A; Kronenwett R; Calvo L; Petry C; Bernard PS; Ruiz-Borrego M; Weber KE; Rodriguez CA; Alvarez IM; Segui MA; Perou CM; Casas M; Carrasco E; Caballero R; Rodriguez-Lescure A
    Breast Cancer Res Treat; 2016 Feb; 156(1):81-9. PubMed ID: 26909792
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cost-effectiveness analysis of prognostic gene expression signature-based stratification of early breast cancer patients.
    Blank PR; Filipits M; Dubsky P; Gutzwiller F; Lux MP; Brase JC; Weber KE; Rudas M; Greil R; Loibl S; Szucs TD; Kronenwett R; Schwenkglenks M; Gnant M
    Pharmacoeconomics; 2015 Feb; 33(2):179-90. PubMed ID: 25404424
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic Value of EndoPredict in Women with Hormone Receptor-Positive, HER2-Negative Invasive Lobular Breast Cancer.
    Sestak I; Filipits M; Buus R; Rudas M; Balic M; Knauer M; Kronenwett R; Fitzal F; Cuzick J; Gnant M; Greil R; Dowsett M; Dubsky P
    Clin Cancer Res; 2020 Sep; 26(17):4682-4687. PubMed ID: 32561662
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Prediction of Distant Recurrence Using EndoPredict Among Women with ER
    Filipits M; Dubsky P; Rudas M; Greil R; Balic M; Bago-Horvath Z; Singer CF; Hlauschek D; Brown K; Bernhisel R; Kronenwett R; Lancaster JM; Fitzal F; Gnant M
    Clin Cancer Res; 2019 Jul; 25(13):3865-3872. PubMed ID: 31064782
    [TBL] [Abstract][Full Text] [Related]  

  • 10. EndoPredict
    Almstedt K; Mendoza S; Otto M; Battista MJ; Steetskamp J; Heimes AS; Krajnak S; Poplawski A; Gerhold-Ay A; Hasenburg A; Denkert C; Schmidt M
    Breast Cancer Res Treat; 2020 Jul; 182(1):137-146. PubMed ID: 32436145
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Prognostic value of EndoPredict test in patients with hormone receptor-positive, human epidermal growth factor receptor 2-negative primary breast cancer screened for the randomized, double-blind, phase III UNIRAD trial.
    Penault-Llorca F; Dalenc F; Chabaud S; Cottu P; Allouache D; Cameron D; Grenier J; Venat Bouvet L; Jegannathen A; Campone M; Debled M; Hardy-Bessard AC; Giacchetti S; Barthelemy P; Kaluzinski L; Mailliez A; Mouret-Reynier MA; Legouffe E; Cayre A; Martinez M; Delbaldo C; Mollon-Grange D; Macaskill EJ; Sephton M; Stefani L; Belgadi B; Winter M; Orfeuvre H; Lacroix-Triki M; Bonnefoi H; Bliss J; Canon JL; Lemonnier J; Andre F; Bachelot T
    ESMO Open; 2024 May; 9(5):103443. PubMed ID: 38692082
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical Validation of EndoPredict in Pre-Menopausal Women with ER-Positive, HER2-Negative Primary Breast Cancer.
    Constantinidou A; Marcou Y; Toss MS; Simmons T; Bernhisel R; Hughes E; Probst B; Meek S; Kakouri E; Georgiou G; Zouvani I; Savvidou G; Kuhl V; Doedt J; Wagner S; Gutin A; Slavin TP; Lanchbury JS; Kronenwett R; Ellis IO; Rakha EA
    Clin Cancer Res; 2022 Oct; 28(20):4435-4443. PubMed ID: 36043530
    [TBL] [Abstract][Full Text] [Related]  

  • 13. EndoPredict predicts for the response to neoadjuvant chemotherapy in ER-positive, HER2-negative breast cancer.
    Bertucci F; Finetti P; Viens P; Birnbaum D
    Cancer Lett; 2014 Dec; 355(1):70-5. PubMed ID: 25218596
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prognostic contribution of mammographic breast density and HER2 overexpression to the Nottingham Prognostic Index in patients with invasive breast cancer.
    Masarwah A; Auvinen P; Sudah M; Dabravolskaite V; Arponen O; Sutela A; Oikari S; Kosma VM; Vanninen R
    BMC Cancer; 2016 Nov; 16(1):833. PubMed ID: 27806715
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The EndoPredict score provides prognostic information on late distant metastases in ER+/HER2- breast cancer patients.
    Dubsky P; Brase JC; Jakesz R; Rudas M; Singer CF; Greil R; Dietze O; Luisser I; Klug E; Sedivy R; Bachner M; Mayr D; Schmidt M; Gehrmann MC; Petry C; Weber KE; Fisch K; Kronenwett R; Gnant M; Filipits M;
    Br J Cancer; 2013 Dec; 109(12):2959-64. PubMed ID: 24157828
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Decision of adjuvant chemotherapy in intermediate risk luminal breast cancer patients: A prospective multicenter trial assessing the clinical and psychological impact of EndoPredict® (EpClin) use (UCBG 2-14).
    Penault-Llorca F; Kwiatkowski F; Arnaud A; Levy C; Leheurteur M; Uwer L; Derbel O; Le Rol A; Jacquin JP; Jouannaud C; Quenel-Tueux N; Girre V; Foa C; Guardiola E; Lortholary A; Catala S; Guiu S; Valent A; Boinon D; Lemonnier J; Delaloge S
    Breast; 2020 Feb; 49():132-140. PubMed ID: 31790959
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of risk classification between EndoPredict and MammaPrint in ER-positive/HER2-negative primary invasive breast cancer.
    Peláez-García A; Yébenes L; Berjón A; Angulo A; Zamora P; Sánchez-Méndez JI; Espinosa E; Redondo A; Heredia-Soto V; Mendiola M; Feliú J; Hardisson D
    PLoS One; 2017; 12(9):e0183452. PubMed ID: 28886093
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Are symptomatic guidelines for chemotherapy appropriate to ER-positive screen-detected breast cancer (SDBC)?
    Bundred NJ; Prasad R; Morris J; Knox WF; Byrne G; Cheung S; Wilson M; Lawrence G
    Breast Cancer Res Treat; 2013 Apr; 138(2):359-68. PubMed ID: 21744241
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of EndoPredict and EPclin With Oncotype DX Recurrence Score for Prediction of Risk of Distant Recurrence After Endocrine Therapy.
    Buus R; Sestak I; Kronenwett R; Denkert C; Dubsky P; Krappmann K; Scheer M; Petry C; Cuzick J; Dowsett M
    J Natl Cancer Inst; 2016 Nov; 108(11):. PubMed ID: 27400969
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Prognostic value of phosphorylated HER2 in HER2-positive breast cancer patients treated with adjuvant trastuzumab.
    Kurebayashi J; Kanomata N; Yamashita T; Shimo T; Mizutoh A; Moriya T; Sonoo H
    Breast Cancer; 2015 May; 22(3):292-9. PubMed ID: 23749689
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.